🔗 Share this article

While the United States continues making unprecedented changes to its vaccination schedules, a particular individual has surfaced unexpectedly: Høeg, a Danish American physician and public health researcher who rose to prominence by questioning Covid vaccinations in the global health crisis and has focused upon alleged fatalities after Covid immunization in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Childhood Vaccine Schedule

Public health authorities had intended to announce sweeping changes to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish national calendar, according to reports – a significant shift that would put the US out of alignment with much of the international standard with little proof for improved outcomes. The announcement has been pushed back until the next year.

In place of the director of the vaccine center, Høeg is set to address the audience at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this year.

A Shift at the Regulatory Body

This interim role might represent a strengthened alliance between the pharmaceutical and biologics centers as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain childhood shot schedules in the US in order to be more in line with Denmark, a society with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – traditionally the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Concerns Over Background

The appointee has no apparent track record in drug development, regulation or leadership, which has been typical for previous heads of the CBER. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a major agency. She has no expertise in pharmaceutical oversight.”

Past directors of the center would “understand regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Objectively, she lacks the kind of background that former directors who ran the center have had.”

The drug center has an enormous range of responsibilities at the agency, Woodcock stated.

“Everybody just focuses on the novel medication approvals, but the generic program clears numerous generic medications. There’s a biologic copycat branch, non-prescription drug unit and more, and every single one need to be supervised,” Dr. Woodcock explained. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a substantial leadership aspect to the role, which supervises more than 5,000 staff members. “It’s a enormous administrative position, if you execute it properly,” she added.

Official Statement and Disputed Programs

When asked about concerns about Dr. Høeg's credentials and whether this selection indicates increased cooperation among regulatory chiefs on vaccines, a press secretary said that the “inquiries are based on inaccurate premises”.

“Her experience aligns with the functions of her job,” the official stated, pointing to the period Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg takes over the commissioner’s controversial fast-track approval initiative, a contentious rapid drug-approval program that reportedly troubled her preceding directors. “By what process are these therapies being chosen for this fast-track system? Who makes the decisions?” Dr. Howard said. “There’s a lot of secrecy occurring at the agency right now.”

In general, he remarked, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of most medications, with the exception of vaccines.”

Public History on Vaccines

Regarding immunizations, Høeg has a more documented, if troubling, past, critics have noted. She released a study using unverified crowd-sourced reports to estimate the frequency of heart inflammation following COVID-19 immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have altered data to imply Covid vaccines are more dangerous than they are.

Included in her “wish list” for the new administration encompassed altering guidelines for novel immunizations and halting “unnecessary” vaccines, she stated following the vote on a podcast. At the FDA, Dr. Høeg has allegedly suggested excluding young men from obtaining COVID-19 vaccines.

“She is an thorough true believer who begins with her conclusions and works backwards to fit the science in a extremely deceptive, fraudulent manner,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|